September 2016

Read more about Omega-3 fatty acid called DHA, can stop a known trigger of lupus

A team of Michigan State University researchers has found that consuming an omega-3 fatty acid called DHA, or docosahexaenoic acid, can stop a known trigger of lupus and potentially other autoimmune disorders.

Read more about Research into fly development provides insights into blood vessel formation

Researchers working with flies at IRB Barcelona describe that the concentration of some small intracellular organelles determines the branching capacity of tracheal cells. Tracheal cells are analogous to the cells that form blood vessels in the human body. The inhibition or stimulation of new blood vessels has implications in cancer and in tissue regeneration.

Read more about Tuberculosis Could be controlled by vitamin D

Research in Veterinary Science reveals that vitamin D supplementation reduces the incidence and severity of tuberculosis (TB) in wild boar and red deer. The pilot study of 40 animals was conducted by a multidisciplinary team of scientists from the University of Surrey (UK), Universidad de Extremadura (Spain), and SME Ingulados (Spain).

Read more about Medtronic Get FDA Clearance of TrailBlazer Angled Peripheral Support Catheter

Medtronic plc announced that the U.S. Food and Drug Administration (FDA) has cleared the TrailBlazer(TM) angled support catheter for use in the peripheral vascular system. Support catheters such as the Trailblazer are often used in endovascular procedures treating complex peripheral artery disease (PAD). FDA clearance was received on September 23, 2016.

Read more about AstraZeneca presents new data on Faslodex at ESMO 2016 congress

AstraZeneca, along with its global biologics research and development arm, MedImmune, will showcase the growing potential of its broad portfolio of cancer medicines through 46 scientific presentations, at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, from 7-11 October 2016.

Read more about Zymeworks and Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement and Bi-Specific Antibody Collaboration

Zymeworks Inc., and Daiichi Sankyo Company, Limited announced that they have entered into a cross-licensing and collaboration agreement to develop proprietary cancer immuno-oncology products

Read more about Aegerion Pharma get Japanese approval for Juxtapid

Aegerion Pharmaceuticals, Inc. announced that Japan's Ministry of Health, Labor & Welfare (MHLW) has approved Juxtapid for patients with homozygous familial hypercholesterolemia (HoFH).